IGF2R, insulin like growth factor 2 receptor, 3482

N. diseases: 166; N. variants: 18
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression disease BEFREE RT‑PCR demonstrated that the mRNA expression levels of IGF2R were downregulated in HCC compared with in TST samples (P=0.004), which was associated with a worse recurrence‑free survival of patients with HCC (P=0.002) and a lower occurrence of cirrhosis (P=0.05). 30720132 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression disease BEFREE DX-2647, a recombinant human antibody, potently neutralizes the action of insulin-like growth factor-II (IGF-II), a ligand for three cell-surface receptors (IGF-IR, insulin receptor A and B isoforms, and the cation-independent mannose-6-phosphate receptor) which is overexpressed in primary human HCC. 29933129 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE The combination of IGF-2+3580 AA homozygosity and IGF-2R 1619 GG homozygosity presented a significant protective effect against HCC (OR=0.16,95% CI=0.08-0.34, P=0.005). 24656929 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease LHGDN These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients. 18322954 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients. 18322954 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE Moreover, these M6P/IGF2R 3'UTR mutations and the TP53 mutations detected previously were mutually exclusive in most of the tumors, suggesting two independent pathways to HCC development, with the TP53 pathway being more favored with increasing radiation dose than the M6P/IGF2R pathway. 17149973 2006
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker disease CTD_human Total RNA was extracted from individual HCCs for assessment of mutations within exons 27, 28, 31, 33, and 34, and aberrant transcript of the M6p/Igf2r gene by reverse transcription (RT)-polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) and RT-PCR analyses, respectively. 15057872 2004
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker disease LHGDN Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells. 12603530 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression disease BEFREE Compared with corresponding non-tumor tissues, expression of the M6P/IGF2R mRNA was decreased in 13/19 (68%) HBV-positive HCC tissues, suggesting that M6P/IGF2R may be involved in HBV-associated hepatocarcinogenesis by the regulation of its expression level. 12736721 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE In conclusion, M6P/IGF2R is mutated in HCCs from throughout Japan with a frequency similar to that in the United States. 11981765 2002
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE The latter is homologous to the human M6P/IGF2r coding sequence which is mutated in human hepatocellular carcinoma. 10411141 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE Recently, it was reported in the United States that loss of heterozygosity (LOH) and mutations in exons 27, 28, and 31 of the M6P/IGF2R gene are frequent in hepatocellular carcinomas (HCCs) and adenomas. 10347113 1999
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE M6P/IGF2R allele loss was also found in cirrhotic tissue of clonal origin adjacent to these dysplastic lesions and HCCs, demonstrating that M6P/IGF2R inactivation occurs early in liver carcinogenesis. 9294214 1997
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker disease BEFREE The frequent allelic loss and homozygous deletion of the M6P/ IGF2r gene suggest that the M6P/IGF2r gene functions as a tumor suppressor gene in the development of HCC. 9570384 1997
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 GeneticVariation disease BEFREE M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. 7493029 1995
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 AlteredExpression disease BEFREE Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. 7639583 1995
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 Biomarker disease HPO
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 CausalMutation disease CGI
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.700 CausalMutation disease CLINVAR
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 AlteredExpression disease BEFREE We chose the strategy to develop a novel compound that allows the improvement of the targeting of the cation-independent mannose 6-phosphate receptor, which is overexpressed in prostate cancer. 31181759 2019
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 Biomarker disease CTD_human The long tail of oncogenic drivers in prostate cancer. 29610475 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 Biomarker disease BEFREE This study is the first to find that the M6P/IGF2R gene is inactivated in prostate cancer. 16304558 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.330 Biomarker disease BEFREE In contrast, Man-6-P/IGF2R binding of endogenous, full-length uPAR solubilized from plasma membranes of the prostate cancer cell line, PC-3, was not inhibited by Man-6-P. Further studies showed that very little (<5%) endogenous uPAR was Man-6-P/IGF2R binding-competent. 12665524 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.320 Biomarker group CTD_human The long tail of oncogenic drivers in prostate cancer. 29610475 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.320 Biomarker disease BEFREE These data indicate MPR300 as crucial player in the autophagy-lysosomal dysfunctions reported in PD and pinpoint MRP300 as a potential biomarker for PD. 27509067 2016